United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - calcium carbonate; calcium lactate gluconate - effervescent tablet - 1.75gram ; 2.263gram

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - calcium lactogluconate, calcium carbonate - tablets - 1000 milligram - calcium

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ferrous fumarate, quantity: 5 mg (equivalent: iron, qty 1.6 mg); heavy magnesium oxide, quantity: 25.8 mg (equivalent: magnesium, qty 15 mg); manganese sulfate monohydrate, quantity: 15 mg (equivalent: manganese, qty 4.9 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600 mg); colecalciferol, quantity: 0.01 mg - tablet, film coated - excipient ingredients: macrogol 400; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; magnesium stearate; crospovidone; colloidal anhydrous silica; maltodextrin; macrogol 6000; maize starch; acacia; potable water; calcium phosphate; fractionated coconut oil; dl-alpha-tocopherol; sucrose - maintain/support healthy teeth ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support muscle function ; maintain/support absorption of dietary (state vitamin/mineral/nutrient)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - calcium folinate 18.6mg equivalent to folinic acid 15 mg - tablet - 15 mg - active: calcium folinate 18.6mg equivalent to folinic acid 15 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose - calcium leucovorin has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions. calcium leucovorin also has shown good results in reducing the toxicity and circumventing the effect of folic acid antagonists, if therapeutically desired.

Australia - English - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - zinc sulfate monohydrate, quantity: 20.6 mg (equivalent: zinc, qty 7.5 mg); cupric sulfate pentahydrate, quantity: 3.928 mg (equivalent: copper, qty 1 mg); manganese sulfate monohydrate, quantity: 5.539 mg (equivalent: manganese, qty 1.8 mg); dried magnesium sulfate, quantity: 317.46 mg (equivalent: magnesium, qty 40 mg); borax, quantity: 2.205 mg (equivalent: boron, qty 0.25 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600 mg); colecalciferol, quantity: 0.005 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; magnesium stearate; maltodextrin; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified talc; allura red ac; polyvinyl alcohol; macrogol 3350; lecithin; maize starch; acacia; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides; polysorbate 80; macrogol 4000 - maintain/support bone health ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Canada - English - Health Canada

quest vitamins a div of purity life health products - calcium (calcium hvp chelate); magnesium (magnesium hvp chelate); potassium (potassium hvp chelate); iron (iron hvp chelate); manganese (manganese hvp chelate); zinc (zinc hvp chelate); copper (copper hvp chelate); iodine (kelp); molybdenum (molybdenum hvp chelate); chromium (chromium hvp chelate); selenium (selenium hvp amino acid chelate) - tablet - 100mg; 100mg; 33mg; 5mg; 5mg; 5mg; 1mg; 50mcg; 50mcg; 10mcg; 10mcg - calcium (calcium hvp chelate) 100mg; magnesium (magnesium hvp chelate) 100mg; potassium (potassium hvp chelate) 33mg; iron (iron hvp chelate) 5mg; manganese (manganese hvp chelate) 5mg; zinc (zinc hvp chelate) 5mg; copper (copper hvp chelate) 1mg; iodine (kelp) 50mcg; molybdenum (molybdenum hvp chelate) 50mcg; chromium (chromium hvp chelate) 10mcg; selenium (selenium hvp amino acid chelate) 10mcg - minerals

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - codeine phosphate hemihydrate; paracetamol - effervescent tablet - 500/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Australia - English - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - zinc gluconate, quantity: 2.3 mg (equivalent: zinc, qty 300 microgram); hydroxyapatite, quantity: 150 mg (equivalent: calcium, qty 59.8 mg; equivalent: phosphorus, qty 27.75 mg); manganese amino acid chelate, quantity: 15 mg (equivalent: manganese, qty 1.5 mg); heavy magnesium oxide, quantity: 207.3 mg (equivalent: magnesium, qty 125 mg); calcium citrate, quantity: 1.13 g (equivalent: calcium, qty 238.15 mg); colecalciferol, quantity: 0.0025 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; titanium dioxide; carnauba wax; hypromellose; croscarmellose sodium; colloidal anhydrous silica; macrogol 400; maize starch; acacia; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides - helps enhance/promote bone healing/repair ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting  therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug ther

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -   usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -